

Only for professional *in vitro* diagnostic use

Product Code : TMG01

Myoglobin Test Device detects cardiac marker myoglobin in human whole blood, serum and plasma.

BACKGROUND INFORMATION

Myoglobin (MYO) is a heme-protein normally found in skeletal and cardiac muscle with a molecular weight of 17.8 kDa. It constitutes about 2 percent of total muscle protein and is responsible with transporting oxygen within the muscle cells. When the muscle cells are damaged, Myoglobin is released to the blood rapidly due to its relatively small size. Following the death of tissue associated with MI, Myoglobin is one of the first markers to rise above normal levels. The level of Myoglobin increases measurably above baseline within 2-4 hours post-infarct, peaking at 9-12 hours, and returning to baseline within 24-36 hours. A number of reports suggest the measurement of Myoglobin as a diagnostic aid in confirming the absence of myocardial infarction with negative predictive values of up to 100% reported at certain time periods after onset of symptoms.

INTENDED USE

Myoglobin Test Device is a rapid immunochromatographic assay for qualitative detection of human cardiac marker myoglobin in human whole blood / serum / plasma to aid diagnosis of myocardial infarction (MI).

REAGENTS

This test device contains anti-Myoglobin antibody coated particles and capture reagent immobilized on the membrane.

METHOD

Myoglobin Test Device is a rapid, qualitative, immunochromatographic assay for the detection of myoglobin in human whole blood / serum / plasma samples. There is capture reagent immobilized to "T" test area of the test. While performing the test, whole blood / serum / plasma sample dropped to the sample well reacts with the particles coated with anti-myoglobin antibodies. This complex migrates to the other end of the membrane by capillary action. If there is Myoglobin in the sample, it binds to capture reagent in the "T" test area and create a visible, colored signal that means the test result is positive. The minimum detection level is 50 ng/mL. If the sample does not contain myoglobin, colored line does not appear in the "T" test area. This means the test result is negative. As a procedural control, a colored line always appears in the "C" control area indicating that proper volume of sample has been introduced and membrane wicking has occurred.

PRECAUTIONS AND LIMITATIONS

1. For professional and *in vitro* diagnostic use only.
 2. Do not use test kit beyond expiry date. The test device is single use. Do not reuse.
 3. The test device should remain in its original sealed pouch until usage. Do not use the test if the seal is broken or the pouch is damaged.
 4. Wear disposable gloves while performing the test.
 5. Use a new dropper for each sample.
 6. All patient samples should be handled as taking capable of transmitting disease into consideration. Observe established precautions against microbiological hazards throughout all procedures and follow the standard procedures for proper disposal of samples.
 7. This test will indicate only the presence or absence of myoglobin in the sample, and should not be used as the only basis for the diagnosis of myocardial infarction.
 8. As with all diagnostic tests, it should be kept in mind that an identification diagnosis can't be based on a single test result. Diagnosis can only be reached by an expert after the evaluation of all clinical and laboratory findings.
 9. Unusually high titers of heterophile antibodies or rheumatoid factor (RF) may affect results. Even if test results are positive, further clinical evaluation should be considered with other clinical information available to the physician.
 10. There is a slight possibility that some whole blood specimens with very high viscosity or which have been stored for more than 2 days may not run properly on the test device. Repeat the test with a serum or plasma specimen from the same patient using a new test device.
- If the test result is negative and clinical symptoms persist, additional testing using other clinical methods is recommended. A negative result does not at any time preclude the possibility of myocardial infarction.

STORAGE

Test device should be kept away from direct sunlight, moisture, heat and radiation sources.
Store at 4 - 30°C (39 - 86°F). Do not freeze.
The test in the original packaging retains stable until expiry date at storage conditions. The test device should be used in maximum one hour after the foil is opened.

SAMPLE COLLECTION AND PREPARATION

The test can be performed using whole blood, serum or plasma. To avoid hemolysis, serum or plasma should be separated from blood as soon as possible.

For Whole Blood Samples: Test should be performed immediately with whole blood samples. Otherwise, whole blood samples should be stored at 2 - 8 °C with anticoagulants (EDTA, heparin, citrate should be used) to avoid coagulation until they are being tested in a period of 2 days after collection.

For Serum Samples: Collect blood into a collection tube without anticoagulant, leave to settle for 30 minutes for blood coagulation and then centrifuge the blood. At the end of centrifuge period remaining supernatant is used as serum.

For Plasma Samples: Collect blood into a collection tube with anticoagulants (EDTA, heparin, citrate should be used) to avoid coagulation of blood sample and then centrifuge the blood. At the end of centrifuge period supernatant is used as plasma.

Do not use turbid, hemolyzed samples. If the sample cannot be tested on the day of collection, store the serum, plasma samples in a refrigerator or freezer. Do not freeze and thaw the serum, plasma samples repeatedly. **Do not freeze whole blood sample.** Bring the samples to room temperature before testing. Frozen samples must be completely thawed and mixed well prior to testing. Turbid test samples should be centrifuged. Using of frozen and thawed samples should be avoided whenever possible, due to the blocking of the membrane by the debris.

Kit components : Test devices, droppers, diluents (for whole blood samples only) and instructions for use.

Additional materials required but not provided : Sample collection tube, centrifuge and timer, lancet (for only fingerstick whole blood), heparinized dispensing bulbs and capillary tubes (for only fingerstick whole blood).

Additional materials recommended but not provided : Micropipettes to deliver mentioned amount of sample in the test procedure, negative and positive control materials

TEST PROCEDURE

1. Take the test device out of its pouch. Bring the tests and whole blood / serum / plasma samples to room temperature.
 2. **For Whole Blood Samples:** Draw whole blood into dropper and put 2 drops (60 µl) into the sample well of the cassette. Immediately after, 1 drop (~40µL) of diluent is added into the sample well and allowed to soak in.
 3. **For Serum / Plasma Samples:** Draw serum / plasma into dropper and put 2 drops (60 µl) into the sample well of the cassette. **Do not use diluent for serum / plasma samples.**
- Avoid the formation of any air bubbles.
3. Depending on the myoglobin concentration in the sample, the test can react even in 5 minutes. Results should be read at 10 minutes as shown below. Results forming after 20 minutes should be regarded as invalid.

INTERPRETATION OF RESULTS

Negative : Only one colored line is visible in "C" area, indicating that myoglobin does not exist.

Positive : Two colored lines are visible in "C" and "T" areas, indicating that myoglobin exists.

Low concentration of myoglobin may cause a faint line in "T" area. Even such a faint line in "T" area should be regarded as "positive".

Invalid : No colored line is visible or only one colored line is visible in "T" area; test should be repeated using a new test device



QUALITY CONTROL

Tests have built in procedural quality control features. When the test is complete, the user will see a colored line in the "C" area of the test on negative samples and a colored line in the "T" and "C" area on positive samples. The appearance of the control "C" line is considered as an internal procedural control. This line indicates that sufficient volume of sample was added as well as valid test result. It is recommended that a negative control and a positive control be used to verify proper test performance as an external control. Users should follow appropriate federal, state and local guidelines concerning the external quality controls.

PERFORMANCE EVALUATION

Sensitivity and Specificity

The Myoglobin Test Device has been evaluated with a leading commercial Myoglobin EIA test using clinical specimens. The results are as below;

Myoglobin Test Device	Method	EIA		Total Results
	Results	Positive	Negative	
	Positive	75	7	82
Total Results	Negative	0	420	420
		75	427	502

Sensitivity: 100%
+ Predictive V: 92 %

Specificity: 98.4%
- Predictive V: 100%

Intra-Assay

Within-run precision has been determined by using replicates of 15 tests using Myoglobin specimen levels at 0 ng/mL, 50 ng/mL, 100 ng/mL, 200 ng/mL, and 400 ng/mL. The specimens were correctly identified >99% of the time.

Inter-Assay

Between-run precision has been determined by 3 independent assays on the same five specimens: 0 ng/mL, 50 ng/mL, 100 ng/mL, 200 ng/mL, and 400 ng/mL of Myoglobin. Myoglobin Test Device have been tested using these specimens. The specimens were correctly identified >99% of the time.

INTERFERING SUBSTANCES

The Myoglobin Test Device has been tested and no interference was observed in specimens containing 110 mg/mL human albumin, 6 mg/mL bilirubin, 10 mg/mL hemoglobin, 5 mg/mL cholesterol and 15 mg/mL triglycerides. The following compounds have also been tested using the Myoglobin Test Device and no interference was observed.

Acetaminophen	Chloramphenicol	Flunarizine Hydrochloride	Nifedipine
Acetoacetic Acid	Chlordiazepoxide	Furosemide	Oxalic Acid
Acetylsalicylic acid	Cilazapril	Gentisic Acid	Oxazepam
Anisodamine	Creatine	Hydrochlorothiazide	Pentoxifyline
Ascorbic Acid	Diclofenac	Isosorbide Mononitrate	Phenobarbital
Atenolol	Digoxin	Labetalol	Quinine
Atorvastatin Calcium	DL-Tyrosine	Metoprolol Tartrate	Ramipril
Caffeine	Ethanol	Moracizine Hydrochloride	Verapamil
Captopril	Felodipine		

REFERENCES

1. Wong SS. Strategic utilization of cardiac markers for diagnosis of acute myocardial infarction. Ann Clin Lab Sci, 26:301-12, 1996.
2. Kagen LJ. Myoglobin methods and diagnostic uses. CRC Crit. Rev. Clin. Lab. Sci., 2:273, 1978.
3. Chapelle JP, et al. Serum myoglobin determinations in the assessment of acute myocardial infarction. Eur. Heart Journal, 3:122, 1982.
4. Hamfelt A, et al. Use of biochemical tests for myocardial infarction in the county of Vasternorrland, a clinical chemistry routine for the diagnosis of myocardial infarction. Scand. J. Clin. Lab. Invest. Suppl., 200:20, 1990.

TÜRKLAB TIBBİ MALZEMELER SAN. TİC. A.Ş.
A.O.S.B 10040 Sok. No:20 Çiğli-Izmir / TURKEY
TEL: +90 232 376 80 81 FAX: +90 232 376 80 40 info@turklab.com.tr www.turklab.com.tr

GESAN PRODUCTION s.r.l.
Via Einaudi, 19 91021 TRE FONTANE -
Campobello di Mazara (TP) ITALY

SYMBOLS USED

